We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Illumina Registers MiSeqDx System in South Korea
News

Illumina Registers MiSeqDx System in South Korea

Illumina Registers MiSeqDx System in South Korea
News

Illumina Registers MiSeqDx System in South Korea

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Illumina Registers MiSeqDx System in South Korea"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Illumina, Inc. has announced that it has received a product approval certificate for the MiSeqDx® Instrument and the MiSeqDx Universal Kit with the Ministry of Food and Drug Safety (MFDS) in South Korea. This successful approval of an Illumina next-generation sequencing (NGS) system is the first step in completing a comprehensive regulatory strategy in the APAC region.

“This is an exciting milestone for the clinical market in South Korea,” said Tim Orpin, Vice President and General Manager for Illumina in the Asia Pacific region. “The MiSeqDx technology enables clinicians to obtain comprehensive and reliable results from NGS-based genetic tests.”

The MiSeqDx Instrument offers users the ability to perform NGS for diagnostic or research applications on a single, easy-to-use system. Designed and validated for the clinical market, the instrument harnesses Illumina’s industry-leading sequencing by synthesis (SBS) chemistry giving laboratories high confidence in their results.

“Illumina is thrilled to receive this regulatory approval,” added Jason Kang, Commercial Leader of Illumina Korea. “This registration permits Illumina to supply clinical laboratories in South Korea with our NGS technology. It will also accelerate the process for us to get other Illumina clinical products into this market in the future.”

Advertisement